Orphomed

VectivBio

This company develops biopharmaceutical treatments for severe rare gastrointestinal conditions, including short bowel syndrome, for patients with orphan diseases.

EnteroBiotix

This biopharmaceutical company develops orally administered microbial therapeutics for patients with gastrointestinal diseases, including irritable bowel syndrome and blood cancers.

Avexegen

This biopharmaceutical company develops peptide therapies to treat gastrointestinal disorders and restore gut health for patients with inflammatory conditions.

cAMPfield

The company develops oral biopharmaceutical medicines for patients with immune-mediated inflammatory diseases, specifically focusing on treatments for inflammatory bowel disease.

Alba Therapeutics Corp

This biopharmaceutical company develops oral peptide therapeutics to treat autoimmune and inflammatory conditions, such as celiac disease, for patients with gastrointestinal disorders.

cAMPfield Therapeutics

The company develops oral medicines for patients with inflammatory bowel disease, specifically focusing on a phosphodiesterase type 4 inhibitor called prifemilast.

Enterbiotix

This company develops orally administered microbiome therapeutics to treat patients with gastrointestinal conditions including irritable bowel syndrome and liver cirrhosis.

Morphic Therapeutic

This biopharmaceutical company develops oral integrin therapies for patients with serious chronic diseases, including autoimmune conditions, fibrosis, and inflammatory bowel disease.